Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-29
2008-01-29
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S106000, C544S170000, C514S231200
Reexamination Certificate
active
07323466
ABSTRACT:
The present invention refers to chemical compounds of formula (I)as well as pharmaceutically acceptable salts and esters thereof, wherein R1to R5have the significance given in claim1. These compounds can be used for the preparation of medicaments.
REFERENCES:
patent: 5574030 (1996-11-01), Masaki et al.
patent: 5852006 (1998-12-01), Masaki et al.
patent: 0435 387 (1991-07-01), None
patent: 1 184 023 (1970-03-01), None
patent: WO 02/22572 (2002-03-01), None
Brown et al,J. Pharm. Pharmacol, vol. 42, (1990) pp. 797-799.
Keller and Wahli: Trends Endocrin. Metab. 1993; 4: 291-296.
Macdonald and Lane: Current Biology vol. 5 pp. 618-621 (1995).
Bentley Jonathan Mark
Dawson Claire Elizabeth
Guba Wolfgang
Hebeisen Paul
Monck Nathaniel
Hoffman-La Roche Inc.
Johnston George W.
Remy Brian C.
Shameem Golam M. M.
Tramaloni Dennis P.
LandOfFree
Morpholine derivatives as 5HT2C receptor agonists for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Morpholine derivatives as 5HT2C receptor agonists for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morpholine derivatives as 5HT2C receptor agonists for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2805886